Emmes Publications | Emmes

Search

Show only items where

Author

Type

Term

Year

Keyword

Found 12 results

Author Title Type [ Year

]

Filters: Author is Anzala, O [Clear All Filters]

2015

Mugo, PM, E Sanders, G Mutua, E van der Elst, O Anzala, B Barin, D Bangsberg, F Priddy, and JE Haberer. 2015. “Understanding Adherence To Daily And Intermittent Regimens Of Oral Hiv Pre-Exposure Prophylaxis Among Men Who Have Sex With Men In Kenya”. Aids Behav 19. Aids Behav: 794-801. http://www.ncbi.nlm.nih.gov/pubmed/25432877.

2014

Omosa-Manyonyi, G, H Park, G Mutua, B Farah, PJ Bergin, D Laufer, J Lehrman, et al.. 2014. “Acceptability And Feasibility Of Repeated Mucosal Specimen Collection In Clinical Trial Participants In Kenya”. Plos One 9. Plos One: e110228. http://www.ncbi.nlm.nih.gov/pubmed/25360819.

Hayes, P, N Fernandez, G Omosa-Manyonyi, J Mpendo, E Karita, E Ruzagira, W Kilembe, et al.. 2014. “Assessment Of Viral Inhibition Activity In Low Seroprevalent Adenovirus-35 Vectored Hiv Vaccines +/- Adjuvanted Protein Or Electroporated Dna”. In Hiv Research For Prevention 2014: Aids Vaccine, Microbicide And Arv-Based Prevention Science (Hivr4P). Hiv Research For Prevention 2014: Aids Vaccine, Microbicide And Arv-Based Prevention Science (Hivr4P). Cape Town, SA. http://hivr4p.org/.

Karita, E, O Anzala, B Gazzard, P Bergin, J Nyombayire, G Omosa, , et al.. 2014. “Clinical Safety And Immunogenicity Of Two Hiv Vaccines Sev-G(Np) And Ad35-Grin In Hiv-Uninfected, Healthy Adult Volunteers”. In Hivr4P (Hiv Research For Prevention). Hivr4P (Hiv Research For Prevention). Cape Town, South Africa. http://hivr4p.org/.

2012

Mutua, G, E Sanders, P Mugo, O Anzala, JE Haberer, D Bangsberg, B Barin, et al.. 2012. “Safety And Adherence To Intermittent Pre-Exposure Prophylaxis (Prep) For Hiv-1 In African Men Who Have Sex With Men And Female Sex Workers”. Plos One 7. Plos One: e33103. http://www.ncbi.nlm.nih.gov/pubmed/22511916.

2010

Jaoko, W, E Karita, K Kayitenkore, G Omosa-Manyonyi, S Allen, S Than, E Adams, et al.. 2010. “Safety And Immunogenicity Study Of Multiclade Hiv-1 Adeno-Viral Vector Vaccine Alone Or As Boost Following A Multiclade Hiv-1 Dna Vaccine In Africa”. Plos One 5. Plos One: e12873. http://www.ncbi.nlm.nih.gov/pubmed/20877623.

Spentzou, A, P Bergin, D Gill, H Cheeseman, A Ashraf, H Kaltsidis, M Cashin-Cox, et al.. 2010. “Viral Inhibition Assay: A Cd8 T Cell Neutralization Assay For Use In Clinical Trials Of Human Immunodeficiency Virus-1 Vaccine Candidates”. J Infect Dis 201. J Infect Dis: 720-729. http://www.ncbi.nlm.nih.gov/pubmed/20132004.

2008

Stevens, W, A Kamali, E Karita, O Anzala, EJ Sanders, W Jaoko, P Kaleebu, et al.. 2008. “Baseline Morbidity In 2,990 Adult African Volunteers Recruited To Characterize Laboratory Reference Intervals For Future Hiv Vaccine Clinical Trials”. Plos One 3. Plos One: e2043. http://www.ncbi.nlm.nih.gov/pubmed/18446196.

Kamali, A, E Karita, K Kayitenkore, P Kaleebu, A Nanvubya, O Anzala, W Jaoko, et al.. 2008. “A Cross-Sectional Study In Eastern And Southern Africa To Characterize Laboratory Reference Intervals In Healthy Adults For Hiv Prevention Trials”. In Aids Vaccine 2008 Conference. Aids Vaccine 2008 Conference. Cape Town, South Africa. http://www.vaccineenterprise.org/conference_archive/2008/index.html.

2007

Ogutu, H, S Wakasiaka, R Malogo, R Ndambuki, J Nyange, G Omosa, O Anzala, et al.. 2007. “Challenges Of Use And Compliance With Effective Contraceptives Among Female Participants In Preventive Hiv Vaccine Trials: The Kenyan Experience”. In Aids Vaccine 2007 Conference. Aids Vaccine 2007 Conference. Seattle, WA. http://www.vaccineenterprise.org/conference_archive/2007/index.html.

2005

Peters, B, W Jaoko, O Anzala, L Judges, Omosa G Manyonyi, A Sharp, K Gray, et al.. 2005. “Phase 2A Dose And Route Study Of A Dna Prime Mva Boost Vaccine Candidate”. In Aids Vaccine 2005 International Conference. Aids Vaccine 2005 International Conference. Montreal, Quebec, Canada.

2004

Farah, BM, S Ogola, O Anzala, J Indangasi, A Tarragona, L Gibiansky, and J Bwayo. 2004. “Development And Validation Of Gamma Interferon Elispot Assay For Hiv-1 Vaccine Trials In Kenya”.